Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Hypersensitivity
Clinical narrative: hypersensitivity reaction; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (hypersensitivity reaction) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 018B21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension (No change in status of condition), Hyperlipidemia (No change in status of condition) and Type 2 diabetes mellitus (No change in status of condition). Concomitant products included HYDROCHLOROTHIAZIDE, VALSARTAN (VALSARTAN & HCTZ) from 24-Sep-2020 to an unknown date, AMLODIPINE from 24-Sep-2020 to an unknown date, POTASSIUM CHLORIDE (KLOR-CON M10) from 24-Sep-2020 to an unknown date, ATORVASTATIN CALCIUM (ATORVASTATIN [ATORVASTATIN CALCIUM]) from 24-Sep-2020 to an unknown date, MELOXICAM from 24-Sep-2020 to an unknown date, OMEPRAZOLE from 24-Sep-2020 to an unknown date, PROPRANOLOL from 24-Sep-2020 to an unknown date, METFORMIN from 24-Sep-2020 to an unknown date, ACETYLSALICYLIC ACID (ASPIRIN 81) from 24-Sep-2020 to an unknown date, MULTIVITAMINS [VITAMINS NOS] from 24-Sep-2020 to an unknown date, BETA CAROTENE from 24-Sep-2020 to an unknown date, CALCIUM, COLECALCIFEROL (CALCIUM +D3) from 24-Sep-2020 to an unknown date, UBIDECARENONE (COQ-10) from 24-Sep-2020 to an unknown date, COLECALCIFEROL (VIT D3) from 24-Sep-2020 to an unknown date and BOSWELLIA SERRATA (BOSWELLIA) from 24-Sep-2020 to an unknown date for an unknown indication.   On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced HYPERSENSITIVITY (hypersensitivity reaction). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) ongoing from 27-May-2021 for Hypersensitivity reaction, at a dose of 3 doses per day; CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) from 29-Mar-2021 to 25-Apr-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; FAMOTIDINE on 29-Mar-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; FAMOTIDINE ongoing from 27-May-2021 for Hypersensitivity reaction, at a dose of 40 mg twice a day; STEROIDS on 25-Apr-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; EPINEPHRINE (EPIPEN) on 25-Apr-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) on 25-Apr-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; HYDROXYZINE HYDROCHLORIDE (HYDROXIZINE) from 11-May-2021 to 22-May-2021 for Hypersensitivity reaction, at an unspecified dose and frequency; HYDROXYZINE HYDROCHLORIDE (HYDROXIZINE) for Hypersensitivity reaction, at a dose of 25 mg once a day; METHYLPREDNISOLONE (MEDROL [METHYLPREDNISOLONE]) from 11-May-2021 to 17-May-2021 for Hypersensitivity reaction, at a dose of Dose pack; METHYLPREDNISOLONE (MEDROL [METHYLPREDNISOLONE]) from 11-Jun-2021 to 16-Jun-2021 for Hypersensitivity reaction, at a dose of Dose pack; MONTELUKAST SODIUM (SINGULAIR) ongoing from 27-May-2021 for Hypersensitivity reaction, at a dose of 10 mg once a day; OMALIZUMAB (XOLAIR) ongoing from 28-Jun-2021 for Hypersensitivity reaction, at an unspecified dose and frequency and TRIAMCINOLONE for Hypersensitivity reaction, at an unspecified dose and frequency. At the time of the report, HYPERSENSITIVITY (hypersensitivity reaction) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Jun-2021, Blood glucose: 151 High. On 12-Jun-2021, Blood glucose: 144 High.         The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular)  was not applicable.   This case was linked to MOD-2021-246794 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 05-Jul-2021: Event details and treatment details.